Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/19/2017
University of Michigan
mi
from
Ann Arbor, MI
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/19/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/19/2017
Ohio State University
mi
from
Columbus, OH
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/19/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Phase II Study of MLN518 in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  10/19/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Phase II Study of MLN518 in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 10/19/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine Alternating With Irinotecan and Temozolomide in Patients With Newly Diagnosed Metastatic Ewing's Sarcoma
Status: Enrolling
Updated:  10/20/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine Alternating With Irinotecan and Temozolomide in Patients With Newly Diagnosed Metastatic Ewing's Sarcoma
Status: Enrolling
Updated: 10/20/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study
Status: Enrolling
Updated:  10/20/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study
Status: Enrolling
Updated: 10/20/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Rush University Medical Center
mi
from
Chicago, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Advocate Christ Medical Center
mi
from
Oak Lawn, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Advocate Christ Medical Center
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Hurley Medical Center
mi
from
Flint, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Phelps County Regional Medical Center
mi
from
Rolla, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Phelps County Regional Medical Center
mi
from
Rolla, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Mercy Hospital Springfield
mi
from
Springfield, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Avera Cancer Institute
mi
from
Sioux Falls, SD
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Gynecologic Oncology Group of Arizona
mi
from
Phoenix, AZ
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Gynecologic Oncology Group of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
The Hartford Hospital
mi
from
Hartford, CT
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Florida Gynecologic Oncology
mi
from
Fort Myers, FL
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Florida Gynecologic Oncology
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
John B. Amos Cancer Center
mi
from
Columbus, GA
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
John B. Amos Cancer Center
mi
from
Columbus, GA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Cadence Cancer Center in Warrenville
mi
from
Warrenville, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Cadence Cancer Center in Warrenville
mi
from
Warrenville, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Michigan Cancer Research Consortium Community Clinical Oncology Program
mi
from
Ann Arbor, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Michigan Cancer Research Consortium Community Clinical Oncology Program
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Oakwood Hospital and Medical Center
mi
from
Dearborn, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Oakwood Hospital and Medical Center
mi
from
Dearborn, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Henry Ford Hospital
mi
from
Detroit, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Genesys Regional Medical Center-West Flint Campus
mi
from
Flint, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Genesys Regional Medical Center-West Flint Campus
mi
from
Flint, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Allegiance Health
mi
from
Jackson, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Sparrow Hospital
mi
from
Lansing, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint Joseph Mercy Port Huron
mi
from
Port Huron, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint Joseph Mercy Port Huron
mi
from
Port Huron, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint Mary's of Michigan
mi
from
Saginaw, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Singing River Hospital
mi
from
Pascagoula, MS
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Singing River Hospital
mi
from
Pascagoula, MS
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Saint John's Clinic-Rolla-Cancer and Hematology
mi
from
Rolla, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Saint John's Clinic-Rolla-Cancer and Hematology
mi
from
Rolla, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  10/20/2017
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
mi
from
Springfield, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 10/20/2017
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials